CN112041320A - 一种可用作肿瘤抑制剂的化合物及其制备方法与应用 - Google Patents

一种可用作肿瘤抑制剂的化合物及其制备方法与应用 Download PDF

Info

Publication number
CN112041320A
CN112041320A CN201880082128.3A CN201880082128A CN112041320A CN 112041320 A CN112041320 A CN 112041320A CN 201880082128 A CN201880082128 A CN 201880082128A CN 112041320 A CN112041320 A CN 112041320A
Authority
CN
China
Prior art keywords
alkyl
chloro
isopropyl
imidazole
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880082128.3A
Other languages
English (en)
Other versions
CN112041320B (zh
Inventor
尹磊
姚郑林
李恒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of CN112041320A publication Critical patent/CN112041320A/zh
Application granted granted Critical
Publication of CN112041320B publication Critical patent/CN112041320B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

一种可用作肿瘤抑制剂的化合物及其制备方法与应用，所述化合物具有如通式I所示结构，包括其立体异构体、对映异构体、外消旋体、顺反异构体、互变异构体、同位素变体。所述化合物可单独或与其他药物组合用于治疗肿瘤或炎症疾病，或者用于治疗MDM2和/或MDM4活性介导的其他障碍或疾病，显示出突出的治疗活性。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201880082128.3A 2017-12-29 2018-12-21 一种可用作肿瘤抑制剂的化合物及其制备方法与应用 Active CN112041320B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711484280 2017-12-29
CN2017114842808 2017-12-29
PCT/CN2018/122796 WO2019128877A1 (zh) 2017-12-29 2018-12-21 一种可用作肿瘤抑制剂的化合物及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN112041320A true CN112041320A (zh) 2020-12-04
CN112041320B CN112041320B (zh) 2023-05-23

Family

ID=67066531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880082128.3A Active CN112041320B (zh) 2017-12-29 2018-12-21 一种可用作肿瘤抑制剂的化合物及其制备方法与应用

Country Status (16)

Country Link
US (1) US11339171B2 (zh)
EP (1) EP3733676A4 (zh)
JP (1) JP2021508727A (zh)
KR (1) KR20200105837A (zh)
CN (1) CN112041320B (zh)
AU (1) AU2018398881A1 (zh)
BR (1) BR112020013069A2 (zh)
CA (1) CA3087110A1 (zh)
CL (1) CL2020001685A1 (zh)
CO (1) CO2020009271A2 (zh)
EA (1) EA202091583A1 (zh)
IL (1) IL275667A (zh)
MX (1) MX2020006816A (zh)
PE (1) PE20211908A1 (zh)
SG (1) SG11202006262TA (zh)
WO (1) WO2019128877A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080787A (zh) * 2011-11-29 2014-10-01 诺华股份有限公司 吡唑并吡咯烷化合物
CN104203952A (zh) * 2012-01-26 2014-12-10 诺华股份有限公司 咪唑并吡咯烷酮化合物
WO2015155332A1 (en) * 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
WO2016001376A1 (en) * 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN106795168A (zh) * 2014-06-12 2017-05-31 阿达梅德公司 作为p53‑mdm2蛋白质‑蛋白质相互作用的抑制剂的包含1,1’,2,5’‑四氢螺[吲哚‑3,2’‑吡咯]‑2,5’‑二酮系统的化合物
CN106794171A (zh) * 2014-04-17 2017-05-31 密执安大学评议会 Mdm2抑制剂和使用其的治疗方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33725A (es) * 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
JP6171003B2 (ja) * 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080787A (zh) * 2011-11-29 2014-10-01 诺华股份有限公司 吡唑并吡咯烷化合物
CN104203952A (zh) * 2012-01-26 2014-12-10 诺华股份有限公司 咪唑并吡咯烷酮化合物
WO2015155332A1 (en) * 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
CN106794171A (zh) * 2014-04-17 2017-05-31 密执安大学评议会 Mdm2抑制剂和使用其的治疗方法
CN106795168A (zh) * 2014-06-12 2017-05-31 阿达梅德公司 作为p53‑mdm2蛋白质‑蛋白质相互作用的抑制剂的包含1,1’,2,5’‑四氢螺[吲哚‑3,2’‑吡咯]‑2,5’‑二酮系统的化合物
WO2016001376A1 (en) * 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017060431A1 (en) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Also Published As

Publication number Publication date
IL275667A (en) 2020-08-31
WO2019128877A1 (zh) 2019-07-04
CO2020009271A2 (es) 2020-08-10
EA202091583A1 (ru) 2020-10-08
CN112041320B (zh) 2023-05-23
CL2020001685A1 (es) 2020-09-25
PE20211908A1 (es) 2021-09-28
US11339171B2 (en) 2022-05-24
JP2021508727A (ja) 2021-03-11
EP3733676A1 (en) 2020-11-04
MX2020006816A (es) 2020-09-03
US20210079007A1 (en) 2021-03-18
CA3087110A1 (en) 2019-07-04
AU2018398881A1 (en) 2020-08-06
KR20200105837A (ko) 2020-09-09
BR112020013069A2 (pt) 2020-12-01
EP3733676A4 (en) 2021-09-01
SG11202006262TA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
CN103664991B (zh) 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
KR101849143B1 (ko) 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
EP3843727A1 (en) Inhibitors of (alpha-v)(beta-6) integrin
EP3843728A1 (en) Inhibitors of (alpha-v)(beta-6) integrin
TW202108590A (zh) 新穎羥基酸衍生物，其製備方法及含彼等之醫藥組合物
CN105051046B (zh) β-氨基羰基类化合物、其制备方法、药物组合物及其用途
RU2011142597A (ru) Производные сложных эфиров аминокислот, их соли и способы применения
JP6951406B2 (ja) フラバグリン誘導体
EP2001890A2 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
CN111315744B (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
AU2019372121A1 (en) Heterocyclic compounds as BET inhibitors
CN102639535A (zh) 稠合杂芳基化合物及其制备方法和应用
JP2022532141A (ja) キナーゼ阻害剤として使用される化合物およびその応用
JP2019537598A (ja) ２−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
JP2023525380A (ja) アザ縮合環状アミド化合物及びその用途
CN112041320B (zh) 一种可用作肿瘤抑制剂的化合物及其制备方法与应用
CN114149428A (zh) 吡啶并环类化合物及其制备方法、中间体、组合物和应用
CN104230922A (zh) 一类五元杂环并吡啶类化合物及其制备方法和用途
CN107674059B (zh) 一种苯并氮杂芳环类化合物及其制备方法和应用
EP2835372B1 (en) Thiophene [2, 3-d]pyrimidine derivative, and preparation method and use thereof
CN111039941B (zh) 一种含氮杂环化合物、其制备方法及应用
CN114222740A (zh) 新型极光激酶抑制剂及其用途
CN104211712B (zh) 含杂芳基哌啶的青蒿素衍生物、其制备方法及应用
KR102335637B1 (ko) 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN113735879B (zh) 一种大环jak抑制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant